pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Half-century after IL-2 discovery, its impact on HIV, cancer and blood safety is highlighted

Oct 9, 2026·read at STAT ↗Positive

Robert Gallo marks the 50-year anniversary of the 1976 paper that described interleukin-2, one of the first cytokines identified and essential for T-cell growth.

He notes that IL-2 enabled the discovery of the first human retroviruses, including the virus that causes a rare leukemia and later HIV, leading to the understanding that HIV causes AIDS.

The cytokine also underpinned the development of the blood-screening test that secured the blood supply and has been leveraged in cancer immunotherapy, illustrating how basic research can generate far-reaching clinical advances.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: 50 years ago, my colleagues and I pursued basic research science that became revolutionary”

read at STAT ↗
1,327 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING2CYCLEPATHUltragenyx Pharmaceutical Inc.
drugs
Immunology3
topics
Oncology13Immunology6Hematology5Infectious Disease3OrthopedicsProstate CancerRare DiseaseVaccines

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Matchpoint makes $150M; KymaThera corrals $80MFierce Biotech
  • 23h agoCaribou to stop R&D work, start ‘substantial’ job cutsBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 23Fierce Biotech Layoff Tracker 2026: Caribou cuts staff, halts pipeline; Foghorn reduces workforce by 40%Fierce Biotech
  • Sep 3Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readoutFierce Biotech